临床试验/NCT01140178

NCT01140178已完成1 期

A Phase la Trial of Photodynamic Therapy With HPPH (2-1 (Hexyloxyethyl)-2-devinylpyropheophorbide-a) for Treatment of Dysplasia, Carcinoma in Situ and T1 Carcinoma of the Oral Cavity and/or Oropharynx.

Roswell Park Cancer Institute1 个研究点分布在 1 个国家目标入组 29 人开始时间: 2010年6月8日最近更新: 2018年10月16日

适应症

干预措施

试验速览

阶段: 1 期
状态: 已完成
发起方: Roswell Park Cancer Institute
入组人数: 29
试验地点: 1
主要终点: Toxicity

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

Recent literature suggests that certain patients with squamous cell cancers of the head and neck region may benefit from photodynamic therapy whether or not they may have received prior therapy, e.g. radiation therapy

详细描述

We propose to initiate a Phase 1 a clinical trial using HPPH and 665 nm light in patients with cancer of the oral cavity and/or oropharynx, including lesions of moderate to severe dysplasia, squamous carcinoma in situ and T1 squamous cells carcinoma. The study will employ a fixed HPPH dose of 4 mg/m2 infused over 1 hour, and 24 hours later light doses escalating from 100 J/cm2 to 125 and 140 J/cm2, respectively. The primary goal is the determination of the maximally tolerated PDT dose. Preliminary evidence for PDT efficacy wil also be obtained.

研究设计

研究类型: Interventional
分配方式: Na
干预模型: Single Group
主要目的: Treatment
盲法: None

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Patients with moderate to severe dysplasia and/or squamous carcinoma-in-situ of the oral cavity and/or oropharynx.
•Patients with T1 squamous cell carcinoma of the oral cavity and/or oropharynx.
•Patient may have primary and/or recurrent lesions to be treated.
•Diagnosis must confirmed by biopsy.
•Prior therapy of any type is allowed.
•Male or female patients at least 18 years old. Female patients must not be pregnant and must be practicing a medically acceptable form of birth control, be sterile or post-menopausal. Male patients should be using a medically acceptable form of birth control or be sterile.
•Patients must have an ECOG score of 0-2 (Appendix A 1 ).
•Patient or legal representative must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure.

排除标准

•Patients with T2 or greater squamous cell carcinoma.
•True tongue base lesions (as determined by the treating physician).
•Patients with severe trismus that prevents adequate access to the lesion for treatment light delivery (as determined by the treating physician).
•Porphyria or hypersensitivity to porphyrin or porphyrin-like compounds.
•Patients with impaired hepatic (alkaline phosphatase (hepatic) or SGOT;:3 times the upper normal limits).
•Patients with minimal impairment of renal function (total serum bilirubin;: 2 mg/dl, serum creatinine;: 2 mg/dl)
•Unwilling or unable to follow protocol requirements.
•Any condition which in the Investigator's opinion deems the patient an unsuitable candidate to receive study drug and or light treatment.
•Patients on concurrent chemotherapy or radiation therapy or less than 4 weeks after the last dose of chemotherapy or radiation therapy.
•Inclusion of Women and Minorities:
•Both men and women and members of all races and ethnic groups are eligible for this study.

研究组 & 干预措施

HPPH

Experimental

a fixed HPPH dose of 4 mg/m2 infused over 1 hour, and 24 hours later light doses escalating from 100 J/cm2 to 125 and 140 J/cm2, respectively.

干预措施: HPPH (Drug)

结局指标

主要结局

Toxicity

时间窗: 6 weeks

To determine the maximally tolerated dose in the oral cavity and/or oropharynx of photodynamic therapy (PDT) using HPPH (2-1 (hexyloxyethyl)-2- devinylpyropheophorbide-a) and 665 nm light.

次要结局

Tumor response(3 months)
Response of dysplasia, CiS and selected patients with T1 squamous cell carcinoma of the oral cavity and/or oropharynx using photodynamic therapy (PDT) with HPPH (2-1 (hexyloxyethyl)-2-devinylpyropheophorbide-a) and 665 nm light.(3 months)
Amount of HPPH in the blood prior to light treatment.(3 months)
Biomarkers, i.e. STAT3 crosslinks and/or activation status of pro-survival signaling molecules before and after PDT treatment.(3 months)
To determine non-invasively HPPH fluorescence and blood flow in To determine non-invasively HPPH fluorescence and blood flow in tumor and surrounding normal tissue before and after PDT(3 months)

研究者

发起方

Roswell Park Cancer Institute

申办方类型

Other

责任方

Sponsor

研究点 (1)

Loading locations...

相似试验

招募中

不适用

Effectiveness of Photobiomodulation Protocols in Radiation-induced Oral Side Effects in H&N Cancer PatientsMucositisHyposalivationXerostomia

NCT05242991Federal University of Rio Grande do Sul132

已完成

2 期

Photodynamic Therapy in Treating Patients With Precancerous Esophageal Conditions or Early Stage Esophageal CancerPrecancerous ConditionEsophageal Cancer

NCT00281736Roswell Park Cancer Institute60

终止

2 期

Interstitial Photodynamic Therapy (PDT) With Temoporfin for Advanced Head and Neck CancersSquamous Cell Carcinoma of the Head and Neck

NCT01415986University of Arkansas1

撤回

2 期

NCT02119728Roswell Park Cancer Institute

已完成

1 期

Photodynamic Therapy in Treating Patients With Lung CancerAdenocarcinoma of the LungLarge Cell Lung CancerRecurrent Non-small Cell Lung CancerSquamous Cell Lung CancerStage 0 Non-small Cell Lung Cancer

NCT01668823Roswell Park Cancer Institute17